Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$10.32 ▼ -0.30
(-2.82%)
MKT CAP: $93.7M • VOL: 3.3K
52W L $5 52W H $12
ICCC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $27.6M | $26.5M | $17.5M |
| YoY Revenue Growth % | +4.3% | +51.6% | — |
| Gross Profit | $11.4M | $7.9M | — |
| Gross Margin % | 41.4% | 30.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.6M | -$1.6M | -$5.7M |
| Operating Margin % | 6.0% | -6.2% | -32.9% |
| Net Income (GAAP) | -$1.0M | -$2.2M | -$5.8M |
| EBITDA (Normalized) | $2.6M | -$1.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.5M | $357.9K | -$4.7M |
| Capital Expenditures (CapEx) | $1.3M | $465.7K | — |
| Free Cash Flow (FCF) | $1.2M | -$107.8K | -$4.7M |
| FCF Margin % | 4.4% | -0.4% | -26.8% |
| Return on Invested Capital (ROIC %) | 4.2% | -4.0% | — |
| Cash & Short-Term Equivalents | $3.8M | $3.8M | — |
| Total Debt (Short + Long Term) | $7.5M | $9.0M | — |
| Total Stockholders' Equity | $27.1M | $27.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ICCC.